Roche to invest $50 B in pharma and diagnostics in US over next five years

Swiss pharma firm Roche will invest $50 billion into the United States of America (USA) in the next five years. GenenTech has also partnered in the initiative. These investments further strengthen Roche’s already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs,  as well as 1,000 jobs at new and expanded facilities.

As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states. The investment will include: 

• Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
• A state-of-the-art gene therapy manufacturing facility in Pennsylvania
• A new 900,000 square foot manufacturing centre to support Roche’s expanding portfolio of next generation weight loss medicines (location to be announced)
• A new manufacturing facility for continuous glucose monitoring in Indiana
• A new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as hub for our new cardiovascular, renal and metabolism research and development efforts
• Significant expansion and upgrading of our existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana and California

Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the US than it imports.